Unity Biotechnology (NASDAQ:UBX) Rating Lowered to “Neutral” at Mizuho

Unity Biotechnology (NASDAQ:UBX) was downgraded by analysts at Mizuho from an “outperform” rating to a “neutral” rating in a research note issued on Friday, MarketBeat reports. They currently have a $1.00 target price on the stock, down from their prior target price of $6.00. Mizuho’s price objective would suggest a potential upside of 22.01% from the company’s previous close.

UBX has been the topic of several other reports. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Unity Biotechnology in a research report on Wednesday, April 23rd. Chardan Capital reissued a “buy” rating and set a $4.00 price objective on shares of Unity Biotechnology in a report on Wednesday, April 23rd.

Unity Biotechnology Stock Performance

NASDAQ UBX opened at $0.82 on Friday. Unity Biotechnology has a twelve month low of $0.70 and a twelve month high of $3.10. The stock has a market capitalization of $14.11 million, a PE ratio of -0.63 and a beta of 1.28. The stock has a 50-day simple moving average of $1.11 and a 200 day simple moving average of $1.38.

Unity Biotechnology (NASDAQ:UBX) last issued its quarterly earnings results on Tuesday, April 22nd. The company reported ($0.43) EPS for the quarter, hitting analysts’ consensus estimates of ($0.43). As a group, equities research analysts forecast that Unity Biotechnology will post -1.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UBX. Financial Harvest LLC bought a new position in shares of Unity Biotechnology during the 1st quarter worth approximately $213,000. SeaCrest Wealth Management LLC acquired a new position in Unity Biotechnology in the first quarter valued at about $29,000. Finally, Bridgeway Capital Management LLC increased its holdings in shares of Unity Biotechnology by 100.0% during the fourth quarter. Bridgeway Capital Management LLC now owns 50,000 shares of the company’s stock worth $49,000 after buying an additional 25,000 shares in the last quarter. Institutional investors own 29.49% of the company’s stock.

Unity Biotechnology Company Profile

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.